Absci Corp (ABSI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Absci Corp (ABSI) has a cash flow conversion efficiency ratio of -0.153x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-26.31 Million) by net assets ($171.97 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Absci Corp (ABSI) liquidity interval to measure how many days the company can operate on defensive assets alone.
Absci Corp - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Absci Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Absci Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Absci Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Neway CNC Equipment Suzhou Co Ltd
SHG:688697
|
0.043x |
|
CTS International Logistics Corp Ltd
SHG:603128
|
0.000x |
|
JinkoSolar Holding Company Limited
NYSE:JKS
|
-0.268x |
|
Cultural Investment Holdings Co Ltd
SHG:600715
|
0.004x |
|
Gui Zhou Tyre Co Ltd
SHE:000589
|
0.040x |
|
Cronos Group Inc
TO:CRON
|
0.012x |
|
Chengdu Information Technology of Chinese Academy of Sciences Co Ltd
SHE:300678
|
0.047x |
|
Changjiang & Jinggong Steel Building Group Co Ltd
SHG:600496
|
0.037x |
Annual Cash Flow Conversion Efficiency for Absci Corp (2019–2025)
The table below shows the annual cash flow conversion efficiency of Absci Corp from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Absci Corp market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $189.45 Million | $-92.92 Million | -0.491x | -21.36% |
| 2024-12-31 | $179.13 Million | $-72.40 Million | -0.404x | -10.17% |
| 2023-12-31 | $176.18 Million | $-64.64 Million | -0.367x | -23.78% |
| 2022-12-31 | $274.41 Million | $-81.34 Million | -0.296x | -79.08% |
| 2021-12-31 | $366.11 Million | $-60.60 Million | -0.166x | -1.10% |
| 2020-12-31 | $67.00 Million | $-10.97 Million | -0.164x | -211.71% |
| 2019-12-31 | $-41.16 Million | $-6.03 Million | 0.147x | -- |
About Absci Corp
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the… Read more